Market Overview:
The global SARS-CoV-2 IgG(RBD) ELISA market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of SARS-CoV-2 infections, rising awareness about diagnostic tests for SARS-CoV-2, and technological advancements in ELISA assay kits. However, the high cost of diagnostic tests and limited availability of skilled professionals are restraining the growth of this market. The global SARS-CoV-2 IgG(RBD) ELISA market is segmented on the basis of type, application, and region. On the basis of type, it is divided into ELISA sets and ELISA kits. The application segment includes hospitals, clinics, disease control and prevention systems etc., which are further subsegmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China Japan India Australia South Korea New Zealand Rest Of APAC), Middle East & Africa (South Africa Saudi Arabia UAE Rest Of MEA).
 ELISA Industry Outlook.svg)
Product Definition:
SARS-CoV-2 IgG(RBD) ELISA is an enzyme-linked immunosorbent assay (ELISA) that uses antibodies to detect the presence of SARS coronavirus 2 (SARS-CoV-2) IgG in a sample. The assay is used to diagnose infection with SARS-CoV-2.
ELISA Sets:
ELISA (enzyme-linked immunosorbent assay) is a widely accepted test for the detection of antibodies in humans and animals. It is also used to detect viruses, bacteria, toxins, and other entities that our body may resist. The SARS-CoV-2 IgG antibody test by Becton Dickinson & Co., Inc. has gained significant traction worldwide since its launch in March 2016 as it provides accurate results within 2 hours along with sensitivity levels higher than 99%.
ELISA Kits:
ELISA (enzyme-linked immunosorbent assay) is a procedure to detect the presence of an antibody in the human body. It is used for detecting and measuring antibodies in humans and other animals. ELISA kits are used by researchers, physicians, hospitals, diagnostic laboratories & research institutes for various applications such as diagnosis of infectious diseases like SARS-CoV-2 infection or any autoimmune diseases.
Application Insights:
Clinical application accounted for the largest share of the global market in 2017. The disease control and prevention system is expected to be the fastest-growing segment over the forecast period owing to its usage in monitoring SARS-CoV-2 infection. It has been observed that majority of SARS patients have antibodies against SARS-CoV-2, which indicates previous exposure to this virus. Thus, continuous monitoring using antiSarsIgG can help prevent new infections and also manage existing ones efficiently.
The hospital application segment is expected to witness substantial growth during the forecast period due largely to rising awareness about early diagnosis and effective management of viral infections among healthcare professionals as well as general population at large thus resulting in increased demand for diagnostic tests such as ELISA test kits from hospitals & clinics across various regions globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a strong research base, high healthcare expenditure and awareness levels coupled with effective regulatory framework for maintaining public health. The U.S., which is at the forefront of this region, has taken several preventive measures against SARS-CoV-2 infection such as isolation and quarantine of infected individuals, enhanced hygiene practices among others.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as increasing population density along with rising international travel and trade activities that are conducive towards virus spread across this region from 2018 to 2030 timeframe. Moreover, economic development in countries like India & China will also help boost demand for these tests over next seven years due to constantly improving healthcare infrastructure in these regions (2018). In addition, government initiatives coupled with free trade agreements between various nations will further fuel regional market growth during same period (2030).
Growth Factors:
- Increasing incidence of SARS-CoV-2 infection
- Growing awareness about the benefits of early diagnosis and treatment
- Rising demand for point-of-care diagnostics
- Technological advancements in ELISA assay development
- Growing number of collaborations and partnerships between diagnostic companies
Scope Of The Report
Report Attributes
Report Details
Report Title
SARS-CoV-2 IgG(RBD) ELISA Market Research Report
By Type
ELISA Sets, ELISA Kits
By Application
Hospital, Clinic, Disease control and prevention system
By Companies
R&D Systems, Thermo Fisher Scientific, Ortho Clinical Diagnostics, BD Biosciences, ZEUS Scientific, Bio-Rad Laboratories, ALPCO, Enzo Life Sciences, BioMérieux, LOEWE Biochemica, Shenzhen YHLO Biotech, LG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global SARS-CoV-2 IgG(RBD) ELISA Market Report Segments:
The global SARS-CoV-2 IgG(RBD) ELISA market is segmented on the basis of:
Types
ELISA Sets, ELISA Kits
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Disease control and prevention system
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- R&D Systems
- Thermo Fisher Scientific
- Ortho Clinical Diagnostics
- BD Biosciences
- ZEUS Scientific
- Bio-Rad Laboratories
- ALPCO
- Enzo Life Sciences
- BioMérieux
- LOEWE Biochemica
- Shenzhen YHLO Biotech
- LG
 ELISA Market Overview.svg)
Highlights of The SARS-CoV-2 IgG(RBD) ELISA Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ELISA Sets
- ELISA Kits
- By Application:
- Hospital
- Clinic
- Disease control and prevention system
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the SARS-CoV-2 IgG(RBD) ELISA Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 ELISA Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The SARS-CoV-2 IgG(RBD) ELISA is a diagnostic test used to determine the presence of antibodies against the SARS-CoV-2 virus.
Some of the major companies in the sars-cov-2 igg(rbd) elisa market are R&D Systems, Thermo Fisher Scientific, Ortho Clinical Diagnostics, BD Biosciences, ZEUS Scientific, Bio-Rad Laboratories, ALPCO, Enzo Life Sciences, BioM©rieux, LOEWE Biochemica, Shenzhen YHLO Biotech, LG.
The sars-cov-2 igg(rbd) elisa market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 SARS-CoV-2 IgG(RBD) ELISA Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 SARS-CoV-2 IgG(RBD) ELISA Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 SARS-CoV-2 IgG(RBD) ELISA Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the SARS-CoV-2 IgG(RBD) ELISA Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global SARS-CoV-2 IgG(RBD) ELISA Market Size & Forecast, 2018-2028
4.5.1 SARS-CoV-2 IgG(RBD) ELISA Market Size and Y-o-Y Growth
4.5.2 SARS-CoV-2 IgG(RBD) ELISA Market Absolute $ Opportunity
Chapter 5 Global SARS-CoV-2 IgG(RBD) ELISA Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
5.2.1 ELISA Sets
5.2.2 ELISA Kits
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global SARS-CoV-2 IgG(RBD) ELISA Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Disease control and prevention system
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global SARS-CoV-2 IgG(RBD) ELISA Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America SARS-CoV-2 IgG(RBD) ELISA Analysis and Forecast
9.1 Introduction
9.2 North America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
9.6.1 ELISA Sets
9.6.2 ELISA Kits
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Disease control and prevention system
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe SARS-CoV-2 IgG(RBD) ELISA Analysis and Forecast
10.1 Introduction
10.2 Europe SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
10.6.1 ELISA Sets
10.6.2 ELISA Kits
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Disease control and prevention system
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific SARS-CoV-2 IgG(RBD) ELISA Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
11.6.1 ELISA Sets
11.6.2 ELISA Kits
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Disease control and prevention system
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America SARS-CoV-2 IgG(RBD) ELISA Analysis and Forecast
12.1 Introduction
12.2 Latin America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
12.6.1 ELISA Sets
12.6.2 ELISA Kits
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Disease control and prevention system
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) SARS-CoV-2 IgG(RBD) ELISA Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Type
13.6.1 ELISA Sets
13.6.2 ELISA Kits
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) SARS-CoV-2 IgG(RBD) ELISA Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Disease control and prevention system
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 SARS-CoV-2 IgG(RBD) ELISA Market: Competitive Dashboard
14.2 Global SARS-CoV-2 IgG(RBD) ELISA Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 R&D Systems
14.3.2 Thermo Fisher Scientific
14.3.3 Ortho Clinical Diagnostics
14.3.4 BD Biosciences
14.3.5 ZEUS Scientific
14.3.6 Bio-Rad Laboratories
14.3.7 ALPCO
14.3.8 Enzo Life Sciences
14.3.9 BioMérieux
14.3.10 LOEWE Biochemica
14.3.11 Shenzhen YHLO Biotech
14.3.12 LG
